Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Disco-interacting protein 2 homolog A (DIP2A) is a cell surface receptor that serves as a primary mediator for the signaling of Follistatin-like 1 (FSTL1), a secreted glycoprotein with potent cardioprotective properties. In the context of cardiovascular health, the binding of FSTL1 to DIP2A activates the PI3K/Akt/mTOR signaling pathway, which is essential for enhancing cardiomyocyte survival and reducing apoptosis following ischemic events like myocardial infarction. The pathway's effect is highly dependent on the post-translational modification of the ligand; glycosylated FSTL1 typically promotes survival, whereas non-glycosylated forms have been shown to induce the proliferation of adult cardiomyocytes, a rare and highly sought-after effect for cardiac regeneration. Beyond its cardiac functions, DIP2A is also involved in angiogenesis and has been implicated in neurodevelopmental processes, including axonal patterning and synaptic transmission. Therapeutic development focusing on this pathway includes the use of recombinant FSTL1 proteins and bioengineered epicardial patches designed to deliver the ligand directly to damaged heart tissue. However, challenges remain due to the dual role of FSTL1, which can promote beneficial repair in the acute phase but may contribute to pathological fibrosis in chronic disease states.
Follistatin-like 1 (FSTL1) binds to the DIP2A receptor on the surface of cardiomyocytes and endothelial cells, triggering the activation of the PI3K/Akt/mTOR signaling pathway. This cascade promotes cell survival by inhibiting pro-apoptotic factors and, in specific contexts such as with non-glycosylated FSTL1, stimulates cardiomyocyte proliferation and angiogenesis to facilitate cardiac repair.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Disco-interacting protein 2 homolog A (DIP2A) (DIP2A).